Zacks Investment Research on MSN4h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...
Gilead, Regeneron have most theoretical PDUFA date risk, says BofA
With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...
STAT22h
Rollout of ‘miracle’ HIV prevention drug is threatened by Trump cuts to global AIDS relief program
PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...
CSRWire3h
Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIV
Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...
Winners and wishers: 8 potential Bay Area drug approvals coming this year
Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...
Major HIV drug maker to cut nearly 150 Bay Area jobs
On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional Office in San Francisco, a major HIV drug maker ...
Explore more
Morningstar2d
Gilead Sciences Inc GILD
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...